• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey: 75% clinical trials collection processes are paperless

Survey: 75% clinical trials collection processes are paperless

June 20, 2016
CenterWatch Staff

SCORR Marketing, a global health science marketing and communications firm, in partnership with Applied Clinical Trials, has released the results of a comprehensive survey on the use of paperless processes in clinical trials.

The report describes current levels of paperless data collection, perspectives on the importance of paperless clinical trials and the processes that have already been adopted.

“From the survey, we discovered that nearly a quarter of users said that more than 75% of their data collection processes are paperless,” said Cliff Echols, director of market intelligence at SCORR Marketing. “Respondents said that the key benefit of going paperless is better data quality, and users said that their companies have primarily implemented processes to obtain trial data source records from electronic medical records (EMR) as well as processes to implement electronic signatures on clinical trial documents.”

Information regarding the benefits and challenges emerging from the adoption of eClinical processes was also gathered, as well as which stakeholders are most resistant to paperless trials and predictions on future company and industry adoption of paperless processes.

“Survey respondents said that the top concerns they are seeing from adopting paperless processes are related to data security,” said Echols.

“We found that the cost of technology and fear of change were the two greatest hindrances to the adoption of paperless processes,” said Lisa Henderson, editor in chief at Applied Clinical Trials, a part of the life sciences unit of UBM. “However, many respondents, particularly those working within a CRO, believe that there will still be a dramatic increase in their company’s use of paperless processes over the next three years.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing